THE PROFESSIONALISM IN CLINICAL PRACTICE SERIES

This eBook release, titled "PART II" is part of the "PROFESSIONALISM IN CLINICAL PRACTICE SERIES." It specifically addresses the optimisation of antibiotic efficacy and safety for infections caused by multi-drug resistant bacteria. The eBook covers a total of twenty distinct topics. Each topic is divided into two parts: keypoints and their references. Each topic typically consists of an average of 12 key points that encompass the relevant subject matter. The following topics are entitled as:

CARABAPENEM ANTIBIOTICS SHOULD BE USED AT A MINIMUM INHIBITORY CONCENTRATION OF 4 µG/ML FOR AMPC-E INFECTIONS
CEFEPIME AS THE PREFERRED TREATMENT FOR ENTEROBACTER. CLOACAE INFECTIONS AND THE UNCERTAINITY OF PIPERACILLIN/TAZOBACTAM AGAINST ESBL-E INFECTIONS
FOR BETA-LACTAM/NON-BETA-LACTAM BETA-LACTAM INHIBITORS, CARBAPENEMASE-PRODUCING ENTEROBACTERIACAE ISOLATES MUST BE ACCURATELY IDENTIFIED. CONSIDERING CEFTOLOZANE-TAZOBACTAM FOR AMPC-E INFECTIONS
NON-BETA LACTAMS COMBINATIONS ARE INITIALLY RECOMMENDED FOR CARBAPENEM RESISTANT ENTEROBACTERIACAE ASSOCIATED UNCOMPLICATED URINARY TRACT INFECTION
TIGECYCLINE AND ERAVACYCLINE ARE EFFECTIVE FOR KLEBSIELLA PRODUCING CARBAPENAMSES, WHILE CEFTAZIDIME-AVIBACTAM AND CEFIDEROCOL ARE PREFERRED ANTIBIOTICS FOR NEW DELHI AND OTHER METALLO--LACTAMASE-PRODUCING INFECTIONS
TIGECYCLINE AND ERAVACYCLINE CAN TREAT CARBAPENEM-RESISTANT ENTEROBACTERIACAE INFECTIONS, BUT MONOTHERAPY MAY INCREASE MORTALITY. POLYMYXINS' CLINICAL EFFICACY AND SUSCEPTIBILITY TESTING RELIABILITY ARE CONCERNS
AVOID COMBINATION ANTIBIOTIC THERAPY FOR CARBAPENEM-RESISTANT ENTEROBACTERIACE INFECTIONS AND USE CONVENTIONAL NON-CARBAPENEM -LACTAM AGENTS
AMINOGLYCOSIDES CAN SUBSTITUTE NEWER BETA-LACTAM/BETA-LACTAMASES INHIBITORS FOR UNCOMPLICATED CYSTITIS CAUSED BY DIFFICULT TO TREAT PSEUDOMONAS AUROGONISA. COLISTIN IS A VIABLE OPTION AND CEFIDEROCOL IS A FEASIBLE ALTERNATIVE
A SECOND ROUND OF ANTIBIOTIC SUSCEPTIBILITY TESTING FOR RECENT -LACTAMS IN PATIENTS WITH UNCOMPLICATED CYSTITIS CAUSED BY DIFFICULT TO TREAT PSEUDOMONAS AUROGONISA IS STRONGLY RECOMMENDED. FOR RECURRENT INFECTIONS, IMIPENEM-CILASTATIN-RELEBACTAM OR CEFIDEROCOL MAY BE CONSIDERED
CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII IS A HEALTHCARE CHALLENGE. AND NEBULIZED ANTIBIOTICS FOR HARD-TO-TREAT RESPIRATORY INFECTIONS STILL DOUBTFUL CLINICAL EFFICACY
AMPICILLIN-SULBACTAM WITH ANOTHER DRUG REDUCED MORTALITY AND NEPHROTOXICITY BEST FOR HIGH-LOAD CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII
HIGH-DOSE AMPICILLIN-SULBACTAM IS RECOMMENDED AS THE MAIN THERAPY FOR CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTIONS. POLYMYXIN B IS RECOMMENDED OVER COLISTIN. TETRACYCLINE DERIVATIVES LIKE MINOCYCLINE AND TIGECYCLINE ARE PREFERRED FOR THEIR LONG-TERM CLINICAL USE
HIGH-DOSE MINOCYCLINE OR TIGECYCLINE WITH ANOTHER AGENT FOR CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTION MANAGEMENT IS ADVISED. AVOID CEFIDEROCOL AND OMADACYCLINE. AT THIS TIME, TRIPLE-COMBINATION THERAPIES ARE NOT ADVISED
NEBULIZED ANTIBIOTICS ARE NOT RECOMMENDED YET FOR TREATING RESPIRATORY INFECTIONS CAUSED BY CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII AND STENOTROPHOMONAS MALTOPHILIA DUE TO LACK OF EVIDENCES ON THE CLINICAL EFFICACY
HIGH DOSE TRIMETHOPRIM / SULFAMETHOXAZOLE, MINOCYCLINE/TIGECYCLINE, CEFIDEROCOL, LEVOFLOXACIN, OR A COMBINATION CAN TREAT STENOTROPHOMONAS MALTOPHILIA. COMBINATION THERAPY IMPROVES RESULTS
STENOTROPHOMONAS MALTOPHILIA ISOLATES EXHIBIT RESISTANCE TO STANDARD DOSE TRIMETHOPRIM / SULFAMETHOXAZOLE, HIGH-DOSE MINOCYCLINE IS RECOMMENDED FOR TREATMENT, BUT CEFTAZIDIME-AVIBACTAM ARE RECOMMENDED FOR SEVERE CASES
RAPID DIAGNOSTICS AND PREDICTIVE SCORING LOSE EFFECTIVENESS. RECOMMENDED: A COMPREHENSIVE ALGORITHM AND ANTIMICROBIAL STEWARDSHIP PROGRAMMES. CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII PNEUMONIA CAN BE TREATED SAFELY AND EFFECTIVELY WITH CEFIDEROCOL OR SULBACTAM / DURLOB

Dettagli